Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 9/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 2/20 | 0.34 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29450178 | 1.00 | — | — | |
| SCHEMBL20772033 | 0.98 | DYRK1A (0.39) | DYRK1AEGFRMAPK1BRD4APP | |
| SCHEMBL29259056 | 0.83 | BRD4 (0.31) | DYRK1AEGFRBRD4 | |
| SCHEMBL6002639 | 0.80 | NUDT1 (0.62) | EGFRMAPK1APP | |
| SCHEMBL29241305 | 0.80 | METAP2 (0.32) | BRD4 | |
| SCHEMBL30917344 | 0.74 | TDO2 (0.39) | DYRK1AEGFRTDO2PIK3C3 | |
| SCHEMBL27461853 | 0.72 | EGFR (0.44) | EGFRTDO2 | |
| SCHEMBL1940496 | 0.71 | KDM4A (0.41) | DYRK1AEGFRKDM4EALDH1A1TDP1 | |
| SCHEMBL29624620 | 0.71 | KDM4A (0.41) | DYRK1AEGFRKDM4EALDH1A1TDP1 | |
| Quinazoline SCHEMBL3259190 | 0.70 | EGFR (0.67) | EGFRTDO2KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | VIIV HEALTHCARE UK (NO. 4) LIMITED | 2022-06-28 | — | — | US | disclosed |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2021-01-28 | — | — | US | disclosed |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2020-02-13 | — | — | US | disclosed |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK NO 4 LTD (GB) | 2019-04-18 | — | — | US | disclosed |
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO 4) LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-05 | — | — | US | disclosed |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-08-20 | — | — | US | disclosed |
| US-20150025240-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-01-22 | — | — | US | disclosed |
| US-8871771-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-10-28 | — | — | US | disclosed |
| US-7902204-B2 | 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-08 | — | — | US | disclosed |
| CN-101941990-A | The prodrug of the piperidine antiviral agents of piperazine and replacement | BRISTOL MYERS SQUIBB CO | 2011-01-12 | — | — | CN | disclosed |
| US-20100210599-A1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-19 | — | — | US | disclosed |
| US-7745625-B2 | Prodrugs of piperazine and substituted piperidine antiviral agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-06-29 | — | — | US | disclosed |
| CN-1953985-B | Prodrugs of piperazine and substituted piperidine antiviral drugs | BRISTOL MYERS SQUIBB CO | 2010-06-09 | — | — | CN | disclosed |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-29 | — | — | US | disclosed |
| CN-1953985-A | Prodrugs of piperazine and substituted piperidine antiviral drugs | BRISTOL MYERS SQUIBB CO (US) | 2007-04-25 | — | — | CN | disclosed |
| CN-1906199-A | Diazaindole-dicarbonyl-piperazinyl antiviral agents | BRISTOL MYERS SQUIBB CO (US) | 2007-01-31 | — | — | CN | disclosed |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT | 2005-09-22 | — | — | US | disclosed |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | SILEO, LLC | 2005-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000849-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20150315218-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | DYRK1A 4052/4885EGFR 3912/4885MAPK1 2472/4885 |
| US-20190111066-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20080125439-A1 | DIAZAINDOLE-DICARBONYL-PIPERAZINYL ANTIVIRAL AGENTS | ZC3HAV1, ZC3HAV1L, EIF2AK2 | DYRK1A 3636/4885EGFR 4319/4885MAPK1 4534/4885 |
| US-20150232414-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20050209246-A1 | Prodrugs of piperazine and substituted piperidine antiviral agents | ZC3HAV1L, CCR5, CCRL2 | DYRK1A 4380/4885EGFR 4123/4885MAPK1 2967/4885 |
| US-20150025240-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20210023098-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | DYRK1A 3741/4885EGFR 3665/4885MAPK1 2626/4885 |
| US-11369624-B2 | Salts of prodrugs of piperazine and substituted piperidine antiviral agents | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20100210599-A1 | PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | ZC3HAV1L, CCR5, CCRL2 | DYRK1A 4380/4885EGFR 4123/4885MAPK1 2967/4885 |
| US-20200046743-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20160361328-A1 | SALTS OF PRODRUGS OF PIPERAZINE AND SUBSTITUTED PIPERIDINE ANTIVIRAL AGENTS | CCR5, ZC3HAV1L, CCRL2 | DYRK1A 3912/4885EGFR 3793/4885MAPK1 2806/4885 |
| US-20050124623-A1 | For example, 2-(4-Benzoyl-piperazin-1-yl)-3-(4-chloro-5H-pyrrolo[3,2-d]pyrimidin-7-yl)-3-oxo-propionitrile; useful for the treatment of HIV and AIDS | CD4, CCR5, PAICS | DYRK1A 4424/4885EGFR 4796/4885MAPK1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.